Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Curated date: 2024/10/03
Curator:
Revision editor(s):
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy HIV negative individual
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Immunological Responder (IR) HIV infected individual
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Immunological Responder HIV infected individual(IR), were defined as patients whose CD4+ T-cell counts/μl equal or is more than 500 or less than 200 after 2 years of receiving complete viral suppression therapy respectively. All HIV-positive subjects were on two nucleoside reverse transcriptase inhibitors (NRTIs) + nonnucleoside reverse transcriptase inhibitors (NNRTIs) or the protease inhibitor-based therapy: Zidovudine/Tenofovir Disoproxil Fumarate (AZT/TDF) + Lamivudine (3TC) + Efavirenz (EFV) or Lopinavir/ritonavir (LPV/r).
- Group 0 sample size Number of subjects in the control (unexposed) group
- 36
- Group 1 sample size Number of subjects in the case (exposed) group
- 28
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 6 months Other exclusion criteria include: Candidates having age over 60 years old; having opportunistic infection; having hepatitis B or C infection; having used rectally administered medications within 48 h before selection; BMI > 30; having a history of inflammatory bowel disease (IBD); having active inflammation affecting the gastro intestines.
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 3
- Matched on Factors on which subjects have been matched on in a case-control study
- age, body mass index
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Source: Additional file 4, figure S4b
Description: Taxonomic differences of fecal microbiota between the immunological responders (IR), and healthy controls (Control) group.
Abundance in Group 1: increased abundance in
Revision editor(s): Patience Onah, WikiWorks
Signature 2
Source: Additional file 4, figure S4b
Description: Taxonomic differences of fecal microbiota between the immunological non-responders (INR) and healthy controls (Control) group.
Abundance in Group 1: decreased abundance in
Revision editor(s): Patience Onah, WikiWorks
Experiment 2
Curated date: 2024/10/03
Curator: Patience Onah
Revision editor(s): Patience Onah, Peace Sandy, WikiWorks
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- immunological non-responders (INR) HIV infected individual
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- immunological non-responders (INR), and INR were defined as patients whose CD4+ T-cell counts/μl equal or is more than 500 or less than 200 after 2 years of receiving complete viral suppression therapy respectively. All HIV-positive subjects were on two nucleoside reverse transcriptase inhibitors (NRTIs) + nonnucleoside reverse transcriptase inhibitors (NNRTIs) or the protease inhibitor-based therapy: Zidovudine/Tenofovir Disoproxil Fumarate (AZT/TDF) + Lamivudine (3TC) + Efavirenz (EFV) or Lopinavir/ritonavir (LPV/r).
- Group 1 sample size Number of subjects in the case (exposed) group
- 30
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 6 months. Other exclusion criteria include: Candidates having age over 60 years old; having opportunistic infection; having hepatitis B or C infection; having used rectally administered medications within 48 h before selection; BMI > 30; having a history of inflammatory bowel disease (IBD); having active inflammation affecting the gastro intestines.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Source: Additional file 4, figure S4 d
Description: Taxonomic differences of fecal microbiota between the, immunological non-responders (INR) and healthy controls (Control) group.
Abundance in Group 1: increased abundance in immunological non-responders (INR) HIV infected individual
NCBI | Quality Control | Links |
---|---|---|
Fusobacterium | ||
Megasphaera | ||
Subdoligranulum | ||
Parasutterella | ||
Alloprevotella | ||
Ruminococcaceae bacterium UCG-005 | ||
Mediterraneibacter gnavus |
Revision editor(s): Patience Onah, WikiWorks
Signature 6
Source: Additional file 4, figure S4 d
Description: Taxonomic differences of fecal microbiota between the immunological non-responders (INR) and healthy controls (Control) group.
Abundance in Group 1: decreased abundance in immunological non-responders (INR) HIV infected individual
Revision editor(s): Patience Onah, WikiWorks
Experiment 3
Curated date: 2024/10/11
Curator: Patience Onah
Revision editor(s): Patience Onah, Peace Sandy, WikiWorks
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- immunological non-responders (INR) HIV infected individual
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Immunological Responder (IR) HIV infected individual
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Immunological Responder HIV infected individual (IR) was defined as patients whose CD4+ T-cell counts/μl equal or is more than 500 or less than 200 after 2 years of receiving complete viral suppression therapy respectively. All HIV-positive subjects were on two nucleoside reverse transcriptase inhibitors (NRTIs) + nonnucleoside reverse transcriptase inhibitors (NNRTIs) or the protease inhibitor-based therapy: Zidovudine/Tenofovir Disoproxil Fumarate (AZT/TDF) + Lamivudine (3TC) + Efavirenz (EFV) or Lopinavir/ritonavir (LPV/r).
- Group 0 sample size Number of subjects in the control (unexposed) group
- 30
- Group 1 sample size Number of subjects in the case (exposed) group
- 28
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 6 months.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Source: Additional file 4, figure S4 f
Description: Taxonomic differences of fecal microbiota between the immunological non-responders (INR) and Immunological Responder (IR) HIV infected individual.
Abundance in Group 1: increased abundance in Immunological Responder (IR) HIV infected individual
NCBI | Quality Control | Links |
---|---|---|
Solobacterium | ||
Dielma | ||
Blautia | ||
Escherichia/Shigella sp. |
Revision editor(s): Patience Onah, WikiWorks
Signature 2
Source: Additional file 4, figure S4 f
Description: Taxonomic differences of fecal microbiota between the immunological non-responders (INR) and Immunological Responder (IR) HIV infected
Abundance in Group 1: decreased abundance in Immunological Responder (IR) HIV infected individual
NCBI | Quality Control | Links |
---|---|---|
Anaerostipes | ||
Eubacterium ruminantium | ||
Alloprevotella | ||
Eubacterium | ||
Ruminiclostridium sp. |
Revision editor(s): Patience Onah, WikiWorks